Overview
Ramiven 200 mg contains Abemaciclib, a targeted therapy belonging to the class of CDK4/6 inhibitors. It is used in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. Abemaciclib works by blocking the activity of cyclin-dependent kinases 4 and 6, thereby slowing cancer cell growth and division. It may be used alone or in combination with other hormonal therapies.





